Bio-Rad Laboratories Earnings Call Balances Growth and Strain

Bio-Rad Laboratories ((BIO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Bio-Rad Laboratories’ latest earnings call carried a cautious tone despite selective bright spots in operations and technology. Management highlighted solid liquidity, strong momentum in digital PCR instruments and active share repurchases, but the narrative was dominated by declining currency-neutral revenue, margin compression, weaker consumables demand and a large GAAP loss tied to its Sartorius stake.

Modest Reported Revenue Growth Masks Underlying Decline

Bio-Rad reported Q1 2026 net sales of about $592 million, up 1.1% from $585 million a year earlier on a reported basis. Once currency effects are stripped out, however, revenue fell 4.2% year over year, underscoring softer underlying demand and regional headwinds.

Digital PCR Instruments Provide a Key Growth Engine

Digital PCR remained a standout as ddPCR instrument revenue jumped 24% year over year. The new QX700 platform has already enabled more than 99% of digital PCR assays ahead of schedule, driving competitive wins, accelerating instrument placements and contributing to both top-line and margin expansion.

Diagnostics Shows Pockets of Strength Despite FX

Clinical Diagnostics delivered reported revenue of roughly $364 million, a 1.9% increase from the prior year even though currency-neutral sales declined 4.1%. Management pointed to continued resilience in quality systems and immunohematology franchises outside the Middle East, which helped soften broader regional and FX pressures.

Robust Balance Sheet Supports Ongoing Capital Returns

The company ended the quarter with cash and short-term investments of $1.565 billion, slightly above the $1.541 billion level at the end of 2025. Bio-Rad continued to return capital, repurchasing 176,000 shares for about $48 million in Q1 and bringing total buybacks to $542 million, or 2.1 million shares, since early 2024.

Healthy Free Cash Flow Conversion Backs Buyback Capacity

Free cash flow came in at $78 million versus $96 million in the prior-year period, reflecting softer earnings and operating cash. Even so, free cash flow represented 153% of non-GAAP net income and the company still has roughly $237 million remaining under its current share repurchase authorization.

Strategic Moves Target Efficiency and Future Growth

Management emphasized operational initiatives such as manufacturing select life science instruments in China for the local market to improve responsiveness and cost. The company is also reprioritizing its R&D portfolio, expects the Stilla acquisition to be accretive by midyear and is pursuing disciplined M&A focused on targets with $100 million to $500 million in revenue.

Lower Currency-Neutral Revenue and Trimmed 2026 Outlook

Currency-neutral revenue fell 4.2% year on year in Q1, prompting a more guarded full-year stance. Updated 2026 guidance now calls for currency-neutral revenue growth ranging from a 3.0% decline to a modest 0.5% increase, with Life Science expected at -3% to -1% and Diagnostics at -3% to +1%.

Middle East Conflict Weighs on Sales and Margins

Geopolitical turmoil in the Middle East remained a significant drag, reducing Q1 revenues by an estimated $11 million. The region, which accounted for more than 9% of Diagnostics revenue in 2025, is expected to be a persistent headwind to both revenue and margins for the rest of 2026.

Non-GAAP Profitability Slides on Volume and Mix

Non-GAAP net income declined to $51 million, or $1.89 per share, from $71 million and $2.54 per share a year earlier as profitability came under pressure. The non-GAAP operating margin compressed to 6.6% from 10.8%, reflecting weaker volumes, geographic mix, and higher costs.

Sartorius Mark-to-Market Hit Drives Large GAAP Loss

On a reported basis, Bio-Rad posted a net loss of $527 million, or $19.55 per diluted share, in the quarter. The loss was largely driven by a $562 million negative change in the fair market value of its holdings in Sartorius AG, which materially distorted GAAP earnings relative to underlying operations.

Margin Headwinds from Manufacturing, Mix and FX

Non-GAAP gross margin declined to 53.1% from 53.8% a year ago, a roughly 70 basis-point drop. Management attributed the pressure to unfavorable manufacturing absorption of around 40 basis points, a shift toward more instrument versus consumable sales, higher freight and fuel surcharges and foreign exchange.

Consumables and Process Chromatography Underperform

Life Science consumables serving academic and biopharma research declined 3.9%, and management pointed to a low-double-digit drop in ddPCR consumables, undermining recurring revenue. Process chromatography remained particularly weak, experiencing a roughly 13% currency-neutral decline year over year and further weighing on the durability of the revenue base.

Softening Cash Generation and Reduced FCF Outlook

Net cash from operating activities slipped to $108 million from $130 million in the prior-year quarter, as working capital and lower earnings took a toll. Free cash flow fell to $78 million from $96 million, and full-year guidance for free cash flow was cut to a range of $290 million to $340 million.

Guidance Signals Caution Amid Persistent Headwinds

For 2026, Bio-Rad now expects currency-neutral revenue growth between -3% and +0.5%, with Life Science and Diagnostics both facing modest declines to flat performance. Management forecasts full-year non-GAAP gross margin of 53% to 54%, operating margin between 10% and 12%, a tax rate near 22% and free cash flow of about $290 million to $340 million, reflecting a conservative stance.

Bio-Rad’s earnings call painted a company balancing promising technology and strong liquidity against difficult macro and regional conditions. Investors will be watching whether digital PCR growth, cost actions and strategic moves can offset consumable softness, Middle East disruptions and the impact of market volatility on its investment holdings over the coming quarters.